Charles Elliott Sigal Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Charles Elliott Sigal.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Charles Elliott Sigal. Charles Elliott Sigal is Director in Adaptimmune Therapeutics PLC ($ADAP) and Director in Surface Oncology, Inc. ($SURF) and Director in Vir Biotechnology, Inc. ($VIR).
Latest Insider Trading Transactions of Charles Elliott Sigal
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ADAP, SURF, VIR
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 25 2021 | VIR | Vir Biotechnology, ... | Sigal Charles Elliott | Director | Option Exercise | A | 45.28 | 6,748 | 305,549 | 6,748 | |
| May 25 2021 | VIR | Vir Biotechnology, ... | Sigal Charles Elliott | Director | Option Exercise | A | 45.28 | 6,748 | 305,549 | 6,748 | |
| May 25 2021 | VIR | Vir Biotechnology, ... | Sigal Charles Elliott | Director | Grant | A | 0.00 | 3,374 | 0 | 3,374 | 0 to 3.4 K |
| May 25 2021 | VIR | Vir Biotechnology, ... | Sigal Charles Elliott | Director | Grant | A | 0.00 | 3,374 | 0 | 3,374 | 0 to 3.4 K |
| Jul 14 2020 | VIR | Vir Biotechnology, ... | Sigal Charles Elliott | Director | Option Exercise | A | 48.71 | 57,777 | 2,814,318 | 57,777 | |
| Jul 14 2020 | VIR | Vir Biotechnology, ... | Sigal Charles Elliott | Director | Option Exercise | A | 48.71 | 57,777 | 2,814,318 | 57,777 | |
| Jul 01 2020 | ADAP | Adaptimmune Therap ... | Sigal Charles Elliott | Director | Option Exercise | A | 1.67 | 184,258 | 307,711 | 184,258 | |
| Jun 12 2020 | SURF | Surface Oncology, ... | Sigal Charles Elliott | Director | Option Exercise | A | 4.35 | 12,000 | 52,200 | 12,000 | |
| Oct 03 2019 | SURF | Surface Oncology, ... | Sigal Charles Elliott | Director | Option Exercise | A | 1.17 | 13,572 | 15,879 | 13,572 | |
| Jul 03 2019 | ADAP | Adaptimmune Therap ... | Sigal Charles Elliott | Director | Option Exercise | A | 0.61 | 234,407 | 142,988 | 234,407 | |
| Jun 06 2019 | SURF | Surface Oncology, ... | Sigal Charles Elliott | Director | Option Exercise | A | 3.69 | 12,100 | 44,649 | 12,100 | |
| Jun 06 2019 | SURF | Surface Oncology, ... | Sigal Charles Elliott | Director | Option Exercise | A | 3.69 | 12,100 | 44,649 | 12,100 | |
| Jul 05 2018 | SURF | Surface Oncology, ... | Sigal Charles Elliott | Director | Option Exercise | A | 16.83 | 8,882 | 149,484 | 8,882 | |
| Jun 26 2018 | ADAP | Adaptimmune Therap ... | Sigal Charles Elliott | Director | Option Exercise | A | 2.18 | 154,809 | 337,484 | 154,809 | |
| Apr 23 2018 | SURF | Surface Oncology, ... | Sigal Charles Elliott | Director | Option Exercise | C | 0.00 | 100,000 | 0 | 0 | |
| Apr 23 2018 | SURF | Surface Oncology, ... | Sigal Charles Elliott | Director | Buy | C | 0.00 | 45,453 | 0 | 45,453 | 0 to 45.5 K |
| Jul 03 2017 | ADAP | Adaptimmune Therap ... | Sigal Charles Elliott | Director | Option Exercise | A | 0.75 | 220,788 | 165,591 | 220,788 | |
| Aug 12 2016 | ADAP | Adaptimmune Therap ... | Sigal Charles Elliott | Director | Option Exercise | A | 1.27 | 184,562 | 234,394 | 184,562 | |
| May 19 2016 | ADAP | Adaptimmune Therap ... | Sigal Charles Elliott | Director | Buy | P | 1.56 | 15,000 | 23,400 | 314,100 | 299.1 K to 314.1 K (+5.02 %) |
| May 18 2016 | ADAP | Adaptimmune Therap ... | Sigal Charles Elliott | Director | Buy | P | 1.55 | 15,000 | 23,250 | 299,100 | 284.1 K to 299.1 K (+5.28 %) |
| May 18 2016 | ADAP | Adaptimmune Therap ... | Sigal Charles Elliott | Director | Buy | P | 1.53 | 15,000 | 22,950 | 284,100 | 269.1 K to 284.1 K (+5.57 %) |
| May 18 2016 | ADAP | Adaptimmune Therap ... | Sigal Charles Elliott | Director | Buy | P | 1.50 | 15,000 | 22,500 | 269,100 | 254.1 K to 269.1 K (+5.90 %) |
Page: 1